Ascelia Pharma completed an Offering and listing Nasdaq Stockholm in March 2019
The Offering was made to the general public in Sweden and Denmark and to institutional investors in Sweden and abroad.
The Offering comprised a maximum of 8,000,000 shares corresponding to SEK 200 million
The subscription price was SEK 25 per share
Subscription period: 21 February 2019 to 5 March 2019
First day of trading was 13 March 2019
The shares are listed on Nasdaq Stockholm (small cap) under the ticker “ACE”
Subscription undertakings:
Alto Investment, Handelsbanken Fonder and the Fourth Swedish National Pension Fund (AP4) and a number of existing shareholders, including Sunstone Capital and Øresund-Healthcare Capital as well as board members and senior executives, and other external investors, undertook to subscribe for shares in the Offering for a total of SEK 150 million
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway.
Headquarter is in Malmö, Sweden, and the company’s shares are listed on Nasdaq Stockholm (ticker: ACE)
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Read our cookie policy
